178 related articles for article (PubMed ID: 23840315)
21. Species-Specific Valid Ternary Interactions of HIV-1 Env-gp120, CD4, and CCR5 as Revealed by an Adaptive Single-Amino Acid Substitution at the V3 Loop Tip.
Koma T; Yokoyama M; Kotani O; Doi N; Nakanishi N; Okubo H; Adachi S; Adachi A; Sato H; Nomaguchi M
J Virol; 2021 Jun; 95(13):e0217720. PubMed ID: 33883222
[TBL] [Abstract][Full Text] [Related]
22. Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region.
Platt EJ; Kuhmann SE; Rose PP; Kabat D
J Virol; 2001 Dec; 75(24):12266-78. PubMed ID: 11711617
[TBL] [Abstract][Full Text] [Related]
23. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.
Tan Q; Zhu Y; Li J; Chen Z; Han GW; Kufareva I; Li T; Ma L; Fenalti G; Li J; Zhang W; Xie X; Yang H; Jiang H; Cherezov V; Liu H; Stevens RC; Zhao Q; Wu B
Science; 2013 Sep; 341(6152):1387-90. PubMed ID: 24030490
[TBL] [Abstract][Full Text] [Related]
24. Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor.
Nolan KM; Del Prete GQ; Jordan AP; Haggarty B; Romano J; Leslie GJ; Hoxie JA
J Virol; 2009 Apr; 83(8):3798-809. PubMed ID: 19193800
[TBL] [Abstract][Full Text] [Related]
25. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
[TBL] [Abstract][Full Text] [Related]
26. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.
Roche M; Jakobsen MR; Ellett A; Salimiseyedabad H; Jubb B; Westby M; Lee B; Lewin SR; Churchill MJ; Gorry PR
Retrovirology; 2011 Nov; 8():89. PubMed ID: 22054077
[TBL] [Abstract][Full Text] [Related]
27. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.
Henrich TJ; Tsibris AM; Lewine NR; Konstantinidis I; Leopold KE; Sagar M; Kuritzkes DR
J Acquir Immune Defic Syndr; 2010 Dec; 55(4):420-7. PubMed ID: 20856130
[TBL] [Abstract][Full Text] [Related]
28. Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors.
Nolan KM; Jordan AP; Hoxie JA
J Virol; 2008 Jan; 82(2):664-73. PubMed ID: 17977968
[TBL] [Abstract][Full Text] [Related]
29. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.
Ogert RA; Ba L; Hou Y; Buontempo C; Qiu P; Duca J; Murgolo N; Buontempo P; Ralston R; Howe JA
J Virol; 2009 Dec; 83(23):12151-63. PubMed ID: 19776131
[TBL] [Abstract][Full Text] [Related]
30. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
[TBL] [Abstract][Full Text] [Related]
31. A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
Moore JP; Kuritzkes DR
Curr Opin HIV AIDS; 2009 Mar; 4(2):118-24. PubMed ID: 19339950
[TBL] [Abstract][Full Text] [Related]
32. Estimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion.
Mulampaka SN; Dixit NM
PLoS One; 2011; 6(5):e19941. PubMed ID: 21647388
[TBL] [Abstract][Full Text] [Related]
33. An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes.
Sterjovski J; Roche M; Churchill MJ; Ellett A; Farrugia W; Gray LR; Cowley D; Poumbourios P; Lee B; Wesselingh SL; Cunningham AL; Ramsland PA; Gorry PR
Virology; 2010 Sep; 404(2):269-78. PubMed ID: 20570309
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
Recordon-Pinson P; Soulié C; Flandre P; Descamps D; Lazrek M; Charpentier C; Montes B; Trabaud MA; Cottalorda J; Schneider V; Morand-Joubert L; Tamalet C; Desbois D; Macé M; Ferré V; Vabret A; Ruffault A; Pallier C; Raymond S; Izopet J; Reynes J; Marcelin AG; Masquelier B;
Antimicrob Agents Chemother; 2010 Aug; 54(8):3335-40. PubMed ID: 20530226
[TBL] [Abstract][Full Text] [Related]
35. Structural dynamics of HIV-1 envelope Gp120 outer domain with V3 loop.
Yokoyama M; Naganawa S; Yoshimura K; Matsushita S; Sato H
PLoS One; 2012; 7(5):e37530. PubMed ID: 22624045
[TBL] [Abstract][Full Text] [Related]
36. Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.
Swenson LC; Chui CK; Brumme CJ; Chan D; Woods CK; Mo T; Dong W; Chapman D; Lewis M; Demarest JF; James I; Portsmouth S; Goodrich J; Heera J; Valdez H; Harrigan PR
Antimicrob Agents Chemother; 2013 Dec; 57(12):6122-30. PubMed ID: 24080655
[TBL] [Abstract][Full Text] [Related]
37. [Conclusions and perspectives. Maraviroc].
Alcamí J
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():49-54. PubMed ID: 19133222
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of primary resistance to HIV entry inhibitors among brazilian patients failing reverse transcriptase/protease inhibitors treatment reveal high prevalence of maraviroc resistance-related mutations.
Alencar CS; Nishiya AS; Ferreira S; Giret MT; Diaz RS; Sabino EC
AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1267-71. PubMed ID: 20977300
[TBL] [Abstract][Full Text] [Related]
39. Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.
Nedellec R; Coetzer M; Lederman MM; Offord RE; Hartley O; Mosier DE
PLoS One; 2011; 6(7):e22020. PubMed ID: 21760945
[TBL] [Abstract][Full Text] [Related]
40. Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.
Baroncelli S; Galluzzo CM; Weimer LE; Pirillo MF; Volpe A; Mercuri A; Cavalli A; Fragola V; Monno L; Degli Antoni A; Ladisa N; Francisci D; Bucciardini R; Floridia M
J Antimicrob Chemother; 2012 Jun; 67(6):1479-85. PubMed ID: 22361986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]